39,400
-0.51%
Close of 9 Nov 2026, in KRW
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Celltrion Pharm
Its shares trade on KOSDAQ under the ticker 068760.KQ. It has been listed since 3 February 2006. In the fiscal year to 31 December 2025, it reported revenue of ₩536.40bn and net income of ₩38.75bn. At that date it held total assets of ₩759.44bn and shareholders' equity of ₩435.96bn.
Celltrion Pharm, Inc. engages in the manufacture and sale of pharmaceuticals. The company is headquartered in Cheongju, Chungcheongbuk-Do. The company went IPO on 2006-02-03. The Company’s products include hepatotonics, analgesics, antipyretics, anti-inflammatory drugs, antihistamines, respiratory apparatus drugs, circularly system drugs, digestives and stomachic drugs, hormone disease drugs, antibiotics, nutrients, tonics, and other drugs. The company also provides ethical drugs and over-the-counter (OTC) drugs. The firm distributes its products in domestic market and overseas markets such as Philippines, Kazakhstan, Cambodia and other Southeast Asia countries.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 3 Feb 2006
- Employees
- 841
Leadership
Pay as last reported
- Mr. Jeong Jin SeoCo-Chairman, since 2009₩1.77bn
- Mr. Jin Seok SeoCo-Chairman, since 2021₩598.0m
- Mr. Jeong Su SeoCo-President, Chief Executive Officer, Director, since 2016₩606.0m
- Mr. Myeong Geun OhCo-President
- Mr. Seung Jae ChoiVice President₩888.0m
- Mr. Yeong Ho YooVice President₩514.0m
- Mr. Chang Seon LeeManaging Director
- Mr. Jin Gyu WangManaging Director, since 2023
- Mr. Deok Gyu ChoiAssistant Managing Director
- Mr. Yeong Seop LeeInternal Auditor
- Mr. Ji Seok YangAssistant Managing Director
- Mr. Yeong Gyun AhnNon-Executive Independent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 19
- Environment
- 21
- Social
- 31
- Governance
- 5
- Carbon reduction policy
- No
- Human rights policy
- No
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Celltrion Pharm manufactures a diverse range of pharmaceuticals including antibiotics and nutrients.
- The company employs 841 full-time staff members to support its operations.
- Ethical drugs and over-the-counter products are available to domestic and international customers.
Weaknesses
- The firm relies on a limited number of overseas markets for distribution.
- Product diversity includes many categories which may complicate supply chain management.
- Headquarters location in Cheongju might limit access to major global talent pools.
Opportunities
- Expanding sales in Southeast Asia countries like the Philippines offers growth potential.
- Increasing demand for hepatotonics and analgesics in emerging markets presents new avenues.
- Growing need for respiratory apparatus drugs can boost overseas revenue significantly.
Threats
- Intense competition in the global pharmaceutical sector could reduce market share.
- Regulatory changes in Kazakhstan and Cambodia may impact distribution operations.
- Fluctuating currency rates in Southeast Asia affect profitability of overseas sales.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.